By Selina Mckee
Patients in England and Wales with ankylosing spondylitis could soon routinely access a wider list of biologic therapies on the National Health Service following new preliminary recommendations from the National Institute for Health and Care Excellence.
In draft guidelines, the Institute has re-affirmed endorsement of AbbVie’s Humira (adalimumab), Pfizer’s Enbrel (etanercept) and Merck Sharp & Dohme’s Simponi (golimumab) as clinically and cost-effective therapies for the condition, a form of spinal arthritis predominantly affecting young males.
